NASDAQ · IMRXHealthcarePharmaceuticals

Immuneering news

$4.13−0.72%

Close Sep 29, 2026 · split-adjusted

Articles · 30 days0English, de-duplicated

Positive0

Neutral0

Negative0

About Immuneering

Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

GlobeNewswire Inc.Aug 26, 5:16 PM ET▲ Positive

The company demonstrated strong Phase 2a efficacy data (17.3-month median overall survival) with favorable tolerability profile and is actively enrolling patients in a pivotal Phase 3 trial. The company's strategic focus on first-line treatment represents a significant market opportunity, and the emphasis on maintaining patient quality of life while treating cancer positions it competitively in the oncology space.

Also mentions IMRX

Articles that tag IMRX but are mainly about other companies.

None recently.

Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology